Ulf Gerdtham
Professor
Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden.
Author
Summary, in English
This study aimed to assess the costs and benefits of three alternative second-line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail to reach glycated hemoglobin (HbA1c) ≤ 7% with metformin treatment alone: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and neutral protamine Hagedorn (NPH) insulin.
Department/s
- Health Economics
- EpiHealth: Epidemiology for Health
Publishing year
2014
Language
English
Pages
591-607
Publication/Series
Diabetes therapy : research, treatment and education of diabetes and related disorders
Volume
5
Issue
2
Full text
Links
Document type
Journal article
Publisher
Springer
Topic
- Endocrinology and Diabetes
Status
Published
Research group
- Health Economics
ISBN/ISSN/Other
- ISSN: 1869-6953